Journal
JOURNAL OF MOLECULAR GRAPHICS & MODELLING
Volume 126, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jmgm.2023.108627
Keywords
Graph neural networks; Unbalanced dataset; Drug discovery
Ask authors/readers for more resources
This research explores the application of Graph Neural Networks (GNNs) in drug development to overcome cost and time limitations. By comparing different datasets and GNN architectures, it provides benchmarking research to guide future investigations and enhance the effectiveness of GNNs in drug discovery and design. While oversampling technique shows potential on imbalanced datasets, further research is needed to optimize its usage and explore alternative solutions for class imbalance.
This research investigates the application of Graph Neural Networks (GNNs) to enhance the cost-effectiveness of drug development, addressing the limitations of cost and time. Class imbalances within classification datasets, such as the discrepancy between active and inactive compounds, give rise to difficulties that can be resolved through strategies like oversampling, undersampling, and manipulation of the loss function. A comparison is conducted between three distinct datasets using three different GNN architectures. This benchmarking research can steer future investigations and enhance the efficacy of GNNs in drug discovery and design. Three hundred models for each combination of architecture and dataset were trained using hyperparameter tuning techniques and evaluated using a range of metrics. Notably, the oversampling technique outperforms eight experiments, showcasing its potential. While balancing techniques boost imbalanced dataset models, their efficacy depends on dataset specifics and problem type. Although oversampling aids molecular graph datasets, more research is needed to optimize its usage and explore other class imbalance solutions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available